Mizuho Securities Thinks Fate Therapeutics’ Stock is Going to Recover

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Fate Therapeutics (FATEResearch Report) yesterday and set a price target of $109.00. The company’s shares closed last Monday at $34.55, close to its 52-week low of $30.14.

According to, Goldstein is a 4-star analyst with an average return of 7.6% and a 37.4% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Neoleukin Therapeutics, and Autolus Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Fate Therapeutics with a $93.13 average price target.

See today’s best-performing stocks on TipRanks >>

Fate Therapeutics’ market cap is currently $3.34B and has a P/E ratio of -16.41.

Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FATE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Read More on FATE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More